Highly potent p21WAF1‐derived peptide inhibitors of CDK‐mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A
- 1 November 2002
- journal article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 60 (5) , 257-270
- https://doi.org/10.1034/j.1399-3011.2002.21014.x
Abstract
The tumour suppressor protein p21(WAF1) plays a central role in regulating eukaryotic cell-cycle progression. Through its association with G1- and S-phase CDK complexes it regulates activation of the retinoblastoma protein (pRb) and E2F transcription factors. Recognition of CDK/cyclin complexes by p21 occurs, at least in part, through a protein-protein interaction with a binding groove on the cyclin subunit. The same groove has been shown to be involved in the recruitment of macromolecular CDK substrates, including pRb and E2F. Blocking of this recruitment site therefore prevents recognition and subsequent phosphorylation of CDK substrates and offers a therapeutic approach towards restoration of p21-like tumour suppression. Starting from the C-terminal cyclin-binding domain of p21 we have identified the minimal and optimized bioactive (152)HAKRRLIF(159) peptide sequence with respect to CDK protein kinase inhibition where pRb is the substrate. The phosphorylation of histone H1, however, which does not contain a recognizable cyclin-binding motif, was unaffected. Detailed structure-activity relationship investigations revealed that the determinants within this sequence are residues Arg(155), Leu(157) and Phe(159) and more completely define the composition of the cyclin-binding motif. A marked increase in potency was obtained upon replacement of the native Ser(153) with an Ala residue in the context of short synthetic peptide inhibitors and significantly, this mutation resulted in comparable affinity with CDK2/cyclin A as does the full-length recombinant p21 (which has CDK2 and cyclin A binding sites). Peptides derived from various proteins known to interact with cyclins were compared for potency and selectivity. A molecular model of the complex between the cyclin groove and the HAKRRLIF peptide was constructed. This model accounts for the observed peptide structure-activity relationships, including the potency enhancement of the LIF sequence occupying the hydrophobic pocket. Furthermore, it provides generic insights into molecular interactions governing cyclin groove recognition and lays the foundation for the development of peptidomimetic inhibitors of CDKs.Keywords
This publication has 28 references indexed in Scilit:
- Mutational Analysis of the Cy Motif from p21 Reveals Sequence Degeneracy and Specificity for Different Cyclin-Dependent KinasesMolecular and Cellular Biology, 2001
- Cyclin A-CDK Phosphorylation Regulates MDM2 Protein InteractionsJournal of Biological Chemistry, 2001
- Inhibition of Cell Proliferation by the PCNA-Binding Region of p21 Expressed as a GFP MiniproteinExperimental Cell Research, 2001
- The C-terminal regulatory domain of p53 contains a functional docking site for cyclin AJournal of Molecular Biology, 2000
- The N-Terminal Domains of Cyclin-Dependent Kinase Inhibitory Proteins Block the Phosphorylation of cdk2/Cyclin E by the CDK-Activating KinaseBiochemical and Biophysical Research Communications, 2000
- Structure–activity relationship of truncated and substituted analogues of the intracellular delivery vector PenetratinChemical Biology & Drug Design, 2000
- Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinityJournal of Molecular Biology, 1998
- Structure of the C-Terminal Region of p21WAF1/CIP1 Complexed with Human PCNACell, 1996
- A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigenCurrent Biology, 1995
- A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesisInternational Journal of Peptide and Protein Research, 1990